BIRC5 and ovarian carcinoma: Based on this meta-analysis, we found that patients with serous and non-serous subtypes of ovarian carcinoma showed no significant differences in survivin expression (OR = 1.14, 95% CI: 0.83–1.58, p < 0.48) (Figure 7).